Ocular Therapeutix (OCUL) Misses Q2 EPS by 12c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.45), $0.12 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $459 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• HP shares slide as tech giant forecasts 2027 PC market slump
• AMC Entertainment launches tender offer for $360M in senior notes
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)